Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen Gets Cost-Sharing, MedImmune A Pipeline Boost In Five-Antibody Collaboration

This article was originally published in The Pink Sheet Daily

Executive Summary

Amgen and the AstraZeneca biologics subsidiary will co-develop and commercialize five monoclonal antibodies in inflammation and respiratory indications, led by brodalumab, which recently posted impressive Phase II data in psoriasis.

You may also be interested in...

Deal Watch: Endo Hopes To Boost Generics Unit With Buy-Out Of Par

J&J is teaming with Achillion to produce a combo regimen for hepatitis C that might compete with offerings from Gilead, AbbVie and Merck. Amgen is dropping out of its collaboration on brodalumab with AstraZeneca due to concerns about suicidality in clinical trials.

Amgen Bows Out Of Partnership With AstraZeneca On Phase III Brodalumab

Company drops deal to co-develop and commercialize the IL-17 blocker in psoriasis, cites reports of suicidal ideation.

Soriot Makes Changes At AstraZeneca As The Pharma Explores Its Options

AstraZeneca’s Soriot makes big moves on his first day on the job – putting a hold on the company’s share-repurchase program and causing speculation that a big acquisition is set for the near future.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts